Tong Ren Tang Technologies Co Ltd Class H (HK:1666)
:1666
Want to see HK:1666 full AI Analyst Report?
1666 Stock Chart & Stats
HK$4.49
-HK$0.01(-0.20%)
At close: 4:00 PM EST
HK$4.49
-HK$0.01(-0.20%)
Day’s Range― - ―
52-Week RangeHK$3.11 - HK$5.52
Previous CloseN/A
Volume468.00K
Average Volume (3M)1.05M
Market Cap
HK$4.24B
Enterprise ValueHK$1.17B
Total Cash (Recent Filing)HK$4.84B
Total Debt (Recent Filing)HK$2.17B
Price to Earnings (P/E)9.1
Beta0.76
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.47%
Share Statistics
EPS (TTM)0.30
Shares Outstanding628,704,000
10 Day Avg. Volume1,287,300
30 Day Avg. Volume1,053,233
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)0.69
Price to Sales (P/S)0.78
P/FCF Ratio3.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$5.25Price Target Upside16.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.35
Revenue Forecast (FY)HK$7.00B
Bulls Say, Bears Say
Bulls Say
Balance Sheet HealthDeclining leverage and steady equity growth give the company durable financial flexibility. Lower debt-to-equity (~0.30) reduces refinancing and interest risk, enabling sustained dividend capacity, strategic M&A or capex and a better buffer through industry cycles over the next several quarters.
Brand & DistributionA legacy Tong Ren Tang brand plus multi-channel distribution (wholesale, retail, clinics and affiliated networks) supports stable demand and pricing power for proprietary TCM products. This structural channel diversity reduces single-channel risk and underpins long-term product mix advantages.
Cash Generation (2025)A strong FCF rebound in 2025 demonstrates the business can generate meaningful internal funds when operations normalize. Sustained cash conversion supports reinvestment, debt reduction and dividend payouts, improving long-term capital allocation flexibility if volatility is controlled.
Bears Say
Revenue DeclineA material top-line decline (-9.1% in 2025) marks a shift from prior growth and poses a durable headwind. Weaker revenue undermines scale economics and constrains reinvestment, suggesting possible structural demand or competitive pressures in TCM that could slow medium-term growth absent recovery.
Margin CompressionCompression of gross and net margins and a sizeable earnings decline reduce sustainable earnings power and ROE. Persistently lower margins limit retained earnings for growth, weaken resilience to cost inflation, and make it harder to sustain dividends or fund strategic initiatives long term.
Cash-Flow VolatilitySevere cash-flow swings (near-zero OCF and negative FCF in 2024) indicate unstable working-capital conversion. This volatility raises lasting liquidity and planning risks, making consistent capex, dividends or debt reduction harder unless management stabilizes cash conversion processes.
Tong Ren Tang Technologies Co News
1666 FAQ
What was Tong Ren Tang Technologies Co Ltd Class H’s price range in the past 12 months?
Tong Ren Tang Technologies Co Ltd Class H lowest stock price was HK$3.11 and its highest was HK$5.52 in the past 12 months.
What is Tong Ren Tang Technologies Co Ltd Class H’s market cap?
Tong Ren Tang Technologies Co Ltd Class H’s market cap is HK$4.24B.
When is Tong Ren Tang Technologies Co Ltd Class H’s upcoming earnings report date?
Tong Ren Tang Technologies Co Ltd Class H’s upcoming earnings report date is Aug 20, 2026 which is in 55 days.
How were Tong Ren Tang Technologies Co Ltd Class H’s earnings last quarter?
Tong Ren Tang Technologies Co Ltd Class H released its earnings results on Mar 27, 2026. The company reported HK$0.049 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.049.
Is Tong Ren Tang Technologies Co Ltd Class H overvalued?
According to Wall Street analysts Tong Ren Tang Technologies Co Ltd Class H’s price is currently Undervalued.
Does Tong Ren Tang Technologies Co Ltd Class H pay dividends?
Tong Ren Tang Technologies Co Ltd Class H pays a Annually dividend of HK$0.207 which represents an annual dividend yield of 4.47%. See more information on Tong Ren Tang Technologies Co Ltd Class H dividends here
What is Tong Ren Tang Technologies Co Ltd Class H’s EPS estimate?
Tong Ren Tang Technologies Co Ltd Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tong Ren Tang Technologies Co Ltd Class H have?
Tong Ren Tang Technologies Co Ltd Class H has 628,704,000 shares outstanding.
What happened to Tong Ren Tang Technologies Co Ltd Class H’s price movement after its last earnings report?
Tong Ren Tang Technologies Co Ltd Class H reported an EPS of HK$0.049 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.745%.
Which hedge fund is a major shareholder of Tong Ren Tang Technologies Co Ltd Class H?
Currently, no hedge funds are holding shares in HK:1666
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tong Ren Tang Technologies Co Ltd Class H
Tong Ren Tang Technologies Co. Ltd., a company founded in 1669 and based in Beijing, People's Republic of China, maintains extensive operations across Mainland China and Hong Kong. Its primary activities center on the manufacturing and sale of traditional Chinese medicine products. The company's involvement is comprehensive, extending to the cultivation, sourcing, and distribution of Chinese medicinal raw materials. Beyond its core offerings, Tong Ren Tang diversifies its product portfolio with items such as ointments, tea beverages, and specialized foot care solutions. The enterprise is also active in the technological advancement and commercialization of biological products, alongside Western pharmaceuticals, cosmetics, and general healthcare goods. Its distribution network includes both wholesale and retail channels for Chinese medicines and health-related products. Furthermore, Tong Ren Tang provides a broad spectrum of services, including medical research and development, Chinese medical consultation and treatment, advertising, internal and external surgical procedures, medical examinations, and hospital management. Additionally, the company engages in the processing of biochemical products, plant extraction, and the production of various food and daily chemical items.
1666 Stock 12 Month Forecast
Average Price Target
HK$5.25
▲(16.93% Upside)
Technical Analysis
Beijing Tong Ren Tang Chinese Medicine Co
―
China Traditional Chinese Medicine Holdings Co
―
CSPC Pharmaceutical Group
―
Wai Yuen Tong Medicine Holdings Limited
―
Pak Fah Yeow International Limited
―
Options Prices
Currently, No data available
---